Stem Cell Therapy for Erectile Dysfunction (SVF – Stromal Vascular Fraction)
This page describes Stromal Vascular Fraction (SVF) stem cell therapy as applied in erectile dysfunction. Let me begin with an important distinction: what is described here is not GMP cultured stem cells expanded in a laboratory over weeks, but fresh SVF obtained from your own adipose tissue in the same session.
What Is Stromal Vascular Fraction (SVF)?
SVF (stromal vascular fraction) is the cell mixture, rich in stem cells, that remains after fat cells (adipocytes) are removed by a specific process from a sample taken from your own adipose tissue by mini-liposuction. SVF is therefore not a single cell type but a community of cells working together. Unlike the GMP culture method, the cells are not expanded; the procedure is autologous (your own tissue) and completed in a single session.
What Does SVF Contain?
SVF is richer than purified stem cells alone; it contains a variety of cells that together support tissue repair:
- Mesenchymal stem cells (ADSCs): Adipose-derived stem cells with the capacity for renewal and differentiation.
- Pericytes: Key cells surrounding microvessels, considered a stem cell source and initiators of tissue repair.
- Endothelial progenitor and endothelial cells: Support the formation of new vessels (angiogenesis).
- Growth factors and cytokines: Stimulate anti-inflammatory activity, wound healing and tissue renewal.
Why Adipose Tissue?
The reason for taking stem cells from fat is straightforward: adipose tissue contains the highest density of mesenchymal stem cells in the body — considerably richer than bone marrow. It can also be obtained easily, with minimal invasiveness and in sufficient quantity by mini-liposuction. These three advantages — richness, ease of access and volume — make adipose tissue the ideal source for SVF.
How Is SVF Therapy Performed?
The procedure is completed in a single session, usually within a few hours:
- 1. Fat harvest: Mini-liposuction from the abdomen or flank under local anaesthesia.
- 2. Separation: The harvested fat is processed in a closed/automated system to separate the SVF.
- 3. Quality control: Cell count and viability are measured.
- 4. Injection: The prepared SVF is injected into penile tissue (corpus cavernosum) with a fine needle.
Advantages of Automated (Closed-System) Processing
The quality of SVF depends directly on how it is separated. The advantages of closed/automated systems over manual methods are:
- Sterility: With no contact with the outside environment, contamination risk is reduced.
- Standardisation: Reproducible, predictable yield and consistency between patients.
- High cell viability: Gentle processing gives a higher proportion of live cells.
- Reliable dose: The number of cells obtained can be measured and reported.
- Speed: The procedure is completed in the same session within a controlled time.
Why Cell Count and Viability Are Critical
In regenerative treatment the cells are the “active substance”. Two technical measurements therefore determine the quality of the treatment: the number of live cells applied (the dose) and the cell viability rate. A low count or low viability can substantially reduce the response to the same procedure. The scientific literature also notes that the viability of fresh (uncultured) cells can decrease during freezing and thawing, which makes repeat injections more difficult. In a high-quality application these values should be measured and reported to the patient; without an answer to the question “how many cells, and how viable”, the outcome cannot be predicted.
Factors Affecting Treatment Success
The result of SVF therapy does not depend on a single factor:
- Age: Tissue repair capacity is generally higher in younger patients.
- Duration and severity of the erectile dysfunction: Response is better in early and mild to moderate cases.
- Cause (vascular / neurogenic): Vasculogenic cases may benefit more from regenerative treatment.
- Comorbidities: Uncontrolled diabetes, smoking and obesity adversely affect the response.
- Cell number and viability: A higher, viable cell dose is associated with better outcomes.
- Combination: Applying together with methods such as shockwave therapy may strengthen the result.
Human Clinical Trials
The effectiveness of regenerative cell therapies in erectile dysfunction is being investigated not only in animal experiments but in an increasing number of human clinical trials. The prominent human studies are:
- Adipose-derived cells (ADRC/SVF) — Haahr et al. (Denmark): In patients with erectile dysfunction after radical prostatectomy (prostate cancer surgery), a single injection of autologous adipose-derived regenerative cells was found to be safe; significant improvement in erectile function scores (IIEF) and the ability to have intercourse was achieved, particularly in continent patients. The results were maintained at 12-month follow-up. (EBioMedicine 2016; Urology 2018)
- Bone marrow mononuclear cells — INSTIN trial, Yiou et al. (France): In 9 patients with post-prostatectomy erectile dysfunction unresponsive to medication, a marked increase in IIEF-EF score of approximately 11 points was reported in the first months after intracavernous injection of bone marrow mononuclear cells; the effect diminished partially over time. (Eur Urol 2016; Eur Urol Focus 2017)
- Diabetic erectile dysfunction — Al Demour et al. (Jordan): Two intracavernous injections of bone marrow-derived mesenchymal stem cells in patients with diabetes-related erectile dysfunction were found safe in both the Phase 1 and the 24-month follow-up Phase 2 trials and produced significant improvement in IIEF-5 and hardness (EHS) scores. The diminishing of the effect over time indicated the need for repeat application. (Urol Int 2018; Basic Clin Androl 2024)
- Systematic reviews and meta-analyses: Recent reviews evaluating the clinical trials together emphasise that cell therapies appear safe and promising, but that larger controlled trials are needed before effectiveness can be regarded as established. (BMC Urology 2025; Eur Urol Focus review 2023)
The common conclusion: regenerative cell therapies appear safe in human studies and do improve erectile function in a proportion of patients; however, the effect generally diminishes partially over time and the method is not yet established as a standard treatment. Correct patient selection, realistic expectations and, where needed, repetition or combination (for example with shockwave therapy) therefore matter.
Who Is Stem Cell (SVF) Therapy Suitable For?
SVF may be considered in patients with mild to moderate and vasculogenic erectile dysfunction who are looking for a regenerative option outside medication, or who wish to support their existing treatment. In situations such as active cancer, active infection or a bleeding disorder, suitability is examined carefully. The decision is made after detailed examination and investigation.
Safety and Side Effects
Because SVF is prepared from the person’s own adipose tissue (autologous), the risk of rejection is low and it has been reported to be well tolerated in human studies. Temporary swelling, bruising or tenderness may occur at the mini-liposuction and injection sites; these resolve within a short time. Because the method is still developing, it is essential that it is performed in a reliable centre and under medical supervision.
SVF, PRP or Exosomes?
All three are regenerative methods: PRP provides growth factors from your own blood; SVF transfers a living cell mixture from your own fat; exosome therapy uses the messenger vesicles of stem cells in cell-free form. In suitable patients the best result is often obtained with a combination of these. Which is right for you is determined by examination.
Key points
- SVF = a fresh, stem cell-rich cell mixture obtained from fat (not GMP culture).
- Adipose tissue has the highest mesenchymal stem cell density and is easily obtained in quantity.
- Procedure: mini-liposuction → closed-system separation → count/viability → penile injection; single session, autologous.
- Automated/closed system: sterility, standardisation, high viability, reliable dose.
- Cell count and viability directly affect success; they should be measured and reported.
- Human trials (Haahr – adipose, Yiou/INSTIN – bone marrow, Al Demour – diabetic; meta-analyses) report safe and promising results.
- The effect generally diminishes partially over time; the method is not yet a standard treatment.
Frequently Asked Questions About Stem Cell (SVF) Therapy
What is SVF (stromal vascular fraction)?
SVF is the cell mixture that remains after fat cells are removed by a specific process from a sample taken from your own adipose tissue by mini-liposuction. It contains mesenchymal stem cells, pericytes, endothelial progenitor cells and growth factors. Unlike GMP cultured stem cells expanded in a laboratory over weeks, it is fresh and applied in the same session.
What is the difference between SVF and GMP cultured stem cells?
With GMP cultured stem cells, the cells are expanded in a laboratory over several weeks. SVF is a fresh cell mixture obtained from your own adipose tissue and applied in the same session without expansion (autologous, point-of-care). This page describes SVF therapy.
Why are stem cells taken from adipose tissue?
Adipose tissue contains the highest density of mesenchymal stem cells in the body, far richer than bone marrow. It can also be obtained easily, with minimal invasiveness and in sufficient quantity by mini-liposuction. It is therefore preferred for SVF.
Does stem cell (SVF) therapy work in erectile dysfunction?
Several human clinical trials using cells of adipose, bone marrow and other origin have reported that regenerative cell therapies are safe and improve erectile function scores (IIEF, EHS) in a proportion of patients. The evidence is promising; however, the effect generally diminishes partially over time and the method is not yet established as a standard treatment.
How is SVF therapy performed and how long does it take?
Mini-liposuction is performed from the abdomen or flank under local anaesthesia; the harvested fat is processed in a closed/automated system to separate the SVF; after cell count and viability control it is injected into penile tissue. It is usually completed in a single session within a few hours.
Why do cell count and cell viability matter?
The number of live cells applied (the dose) and the viability rate of those cells are the most important technical factors directly affecting the treatment response. In a high-quality application, cell count and viability should therefore be measured and reported.
What is the advantage of automated closed-system processing?
Closed/automated systems provide sterility with reduced contamination risk, standardised and reproducible yield, higher cell viability and a more reliable dose. They offer an advantage in quality and safety over manual methods.
What affects the success of the treatment?
Age, the duration and severity of the erectile dysfunction, its cause (vascular or neurogenic), accompanying diabetes, smoking and obesity, as well as the number and viability of the cells applied and combination treatments such as shockwave therapy, all affect success.
Is stem cell (SVF) therapy safe?
Because SVF is prepared from the person’s own adipose tissue (autologous), the risk of rejection is low and it has been reported to be well tolerated in human studies. Temporary swelling or bruising may occur. As the method is still developing, a reliable centre and medical supervision are essential.
How much does stem cell (SVF) therapy cost?
Cost varies with the system used, the scope of the procedure, any combination and the individual situation, and under Turkish healthcare regulations fixed prices cannot be published. For current information you may contact the clinic.
Whether SVF (stem cell) therapy suits you is determined by examination, investigation and the choice of the right system. Get in touch for an assessment or an appointment.
Scientific References
- Haahr MK, Jensen CH, Toyserkani NM, et al. Safety and Potential Effect of a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial. EBioMedicine. 2016;5:204–210.
- Haahr MK, Harken Jensen C, Toyserkani NM, et al. A 12-Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients With Erectile Dysfunction Following Radical Prostatectomy. Urology. 2018;121:203.e6–203.e13.
- Yiou R, Hamidou L, Birebent B, et al. Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study (INSTIN). Eur Urol. 2016;69(6):988–991.
- Yiou R, Hamidou L, Birebent B, et al. Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial. Eur Urol Focus. 2017;3(6):643–645.
- Al Demour S, Jafar H, Adwan S, et al. Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells Injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial. Urol Int. 2018;101(3):358–365.
- Al Demour S, Adwan S, Jafar H, Alhawari H, Awidi A. Stem cell therapy in diabetic men with erectile dysfunction: a 24-month follow-up of safety and efficacy of two intracavernous autologous bone marrow-derived mesenchymal stem cells injections — an open-label phase 2 clinical trial. Basic Clin Androl. 2024;34:9.
- Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–228.
- European Association of Urology (EAU). Guidelines on Sexual and Reproductive Health — Erectile Dysfunction (regenerative treatments are regarded as developing methods). 2024.
This content is for general information only and does not replace examination by a specialist. SVF (stem cell) therapy is a developing method; it is not yet established as a standard treatment in erectile dysfunction and results vary between individuals. For diagnosis and treatment, please consult a specialist physician.